$250 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 38 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 43.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTGN | Sell | VISTAGEN THERAPEUTICS INC | $36,943,000 | +41.1% | 11,728,033 | -4.6% | 14.76% | +56.3% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $33,019,000 | +57.5% | 987,406 | -3.0% | 13.20% | +74.6% |
| CLDX | New | CELLDEX THERAPEUTICS INC NEWput | $16,720,000 | – | 500,000 | +100.0% | 6.68% | – |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $10,144,000 | +108.9% | 160,500 | +41.8% | 4.05% | +131.5% |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | $8,945,000 | +24.9% | 108,000 | 0.0% | 3.58% | +38.5% | |
| BLSA | BCLS ACQUISITION CORP | $8,878,000 | -0.4% | 843,122 | 0.0% | 3.55% | +10.4% | |
| VSTM | Sell | VERASTEM INC | $8,215,000 | +45.0% | 2,018,433 | -12.0% | 3.28% | +60.7% |
| ISEE | Sell | IVERIC BIO INC | $7,888,000 | -19.2% | 1,250,000 | -20.8% | 3.15% | -10.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $7,772,000 | +5.3% | 417,409 | +1.2% | 3.11% | +16.7% |
| SEEL | Buy | SEELOS THERAPEUTICS INC | $7,550,000 | -12.0% | 2,860,000 | +66.3% | 3.02% | -2.5% |
| KURA | Sell | KURA ONCOLOGY INC | $7,368,000 | -51.4% | 353,398 | -34.2% | 2.94% | -46.2% |
| EPIX | Sell | ESSA PHARMA INC | $6,654,000 | -20.2% | 232,896 | -18.9% | 2.66% | -11.5% |
| CLSD | Sell | CLEARSIDE BIOMEDICAL INC | $6,410,000 | +60.8% | 1,316,268 | -18.4% | 2.56% | +78.2% |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $6,331,000 | -13.7% | 604,074 | -3.0% | 2.53% | -4.3% |
| VINC | Buy | VINCERX PHARMA INC | $6,214,000 | -18.3% | 478,401 | +21.4% | 2.48% | -9.4% |
| CYT | New | CYTEIR THERAPEUTICS INC | $5,944,000 | – | 277,777 | +100.0% | 2.38% | – |
| JYAC | JIYA ACQUISITION CORP | $5,591,000 | +1.0% | 562,500 | 0.0% | 2.23% | +11.9% | |
| ATHA | Buy | ATHIRA PHARMA INC | $4,373,000 | -40.6% | 427,060 | +6.8% | 1.75% | -34.1% |
| ALGS | New | ALIGOS THERAPEUTICS INC | $4,368,000 | – | 214,254 | +100.0% | 1.75% | – |
| SELB | Buy | SELECTA BIOSCIENCES INC | $4,283,000 | +15.0% | 1,024,668 | +24.5% | 1.71% | +27.5% |
| CMRX | Sell | CHIMERIX INC | $4,073,000 | -40.3% | 509,164 | -28.1% | 1.63% | -33.8% |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $4,004,000 | -8.8% | 392,500 | 0.0% | 1.60% | +1.0% | |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $3,890,000 | +25.9% | 149,495 | +53.2% | 1.56% | +39.6% |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $3,776,000 | -61.9% | 561,011 | -48.8% | 1.51% | -57.7% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $3,539,000 | -38.0% | 206,126 | -19.2% | 1.41% | -31.3% |
| EYPT | Sell | EYEPOINT PHARMACEUTICALS INC | $3,325,000 | -14.1% | 369,863 | -3.0% | 1.33% | -4.8% |
| GHRS | New | GH RESEARCH PLCordinary shares | $3,260,000 | – | 150,000 | +100.0% | 1.30% | – |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $3,073,000 | -61.6% | 175,000 | -44.9% | 1.23% | -57.5% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $2,966,000 | -37.4% | 685,000 | -27.1% | 1.18% | -30.6% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $2,894,000 | -67.4% | 50,945 | -57.0% | 1.16% | -63.9% |
| RAIN | New | RAIN THERAPEUTICS INC | $2,521,000 | – | 162,245 | +100.0% | 1.01% | – |
| New | CATABASIS PHARMACEUTICALS IN | $2,476,000 | – | 1,173,674 | +100.0% | 0.99% | – | |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $1,893,000 | +425.8% | 329,134 | +322.0% | 0.76% | +481.5% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $1,483,000 | -17.1% | 60,000 | -26.8% | 0.59% | -8.1% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $1,415,000 | +1.4% | 10,000 | -28.6% | 0.56% | +12.3% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $1,316,000 | -8.1% | 301,904 | -4.3% | 0.53% | +1.9% |
| NVAX | Sell | NOVAVAX INC | $491,000 | -13.7% | 2,315 | -26.2% | 0.20% | -4.4% |
| NUVBWS | Sell | NUVATION BIO INC*w exp 07/07/202 | $236,000 | -5.2% | 90,832 | -2.7% | 0.09% | +4.4% |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -13,856 | -100.0% | -0.16% | – |
| FDMT | Exit | 4D MOLECULAR THERAPEUTICS IN | $0 | – | -20,000 | -100.0% | -0.31% | – |
| INSM | Exit | INSMED INC | $0 | – | -42,500 | -100.0% | -0.52% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -9,000 | -100.0% | -0.56% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -45,000 | -100.0% | -0.63% | – |
| VINCW | Exit | VINCERX PHARMA INC*w exp 12/24/202 | $0 | – | -520,000 | -100.0% | -0.76% | – |
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -90,000 | -100.0% | -1.20% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -200,289 | -100.0% | -1.60% | – |
| PRAX | Exit | PRAXIS PRECISION MEDICINES I | $0 | – | -154,229 | -100.0% | -1.82% | – |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -407,055 | -100.0% | -2.07% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -357,689 | -100.0% | -2.09% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -661,565 | -100.0% | -2.56% | – | |
| CRIS | Exit | CURIS INC | $0 | – | -767,500 | -100.0% | -3.13% | – |
| ETNB | Exit | 89BIO INC | $0 | – | -393,548 | -100.0% | -3.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.